The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.
Open accessAbstract
Leukotriene B4 (LTB4) is a product of the 5-lipoxygenase pathway of arachidonic acid metabolism. LTB4 is a potent chemotactic factor for neutrophils and has been postulated to play an important role in a variety of pathological conditions including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. The role of LTB4 in such diseases has not yet been defined but in this paper we provide direct evidence that LTB4 plays a critical role in a murine model of RA. CP-105,696, (+)-1-(3S,4R)-[3-(4-phenylbenzyl)- 4-hydroxychroman-7-yl]cyclopentane carboxylic acid, is an LTB4 receptor antagonist that inhibits LTB4 binding to human neutrophil membranes with an IC50 of 3.7 nM and inhibits LTB4-induced chemotaxis of these cells with an IC50 of 5.2 nM. CP-105,696 inhibits LTB4-induced neutrophil influx in mouse skin when administered orally with an ED50 of 4.2 mg/kg. CP-105,696 had a dramatic effect on both the clinical symptoms and histological changes of murine collagen-induced arthritis when administered at doses of 0.3-10 mg/kg. Inhibition was not associated with suppression of the humoral immune response to collagen and was equally effective if drug treatment was commenced just prior to the onset of arthritis or throughout the experiment. These results suggest that LTB4 receptor antagonists may be effective therapeutic agents for the treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford-Hutchinson, A. W., Bray, M. A., Doig, M. V., Shipley, M. E., & Smith, M. J. H. (1980) · Nature · doi:10.1038/286264a0 · Cited by 2,060
Self-citationTreatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Immunisation against heterologous type II collagen induces arthritis in mice
Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A., & Mosedale, B. (1980) · Nature · doi:10.1038/283666a0 · Cited by 1,025
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis
Trentham, D. E., Dynesius-Trentham, R. A., Orav, E. J., Combitchi, D., Lorenzo, C., Sewell, K. L., Hafler, D. A., & Weiner, H. L. (1993) · Science · doi:10.1126/science.8378772 · Cited by 624
Klickstein, L. B., Shapleigh, C., & Goetzl, E. J. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109947 · Cited by 345
Ferrante, A., & Thong, Y. H. (1978) · Journal of Immunological Methods · doi:10.1016/0022-1759(78)90143-6 · Cited by 333
Wooley, P. H., Dutcher, J., Widmer, M. B., & Gillis, S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6602 · Cited by 293
Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
VAN DEN BERG, W. B., JOOSTEN, L. A. B., HELSEN, M., & VAN DE LOO, F. A. J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06517.x · Cited by 251
Piguet, P. F., Grau, G. E., Vesin, C., Loetscher, H., Gentz, R., & Lesslauer, W. (1992) · PubMed Central · Cited by 232
Wooley, P. H., Whalen, J. D., Chapman, D. L., Berger, A. E., Richard, K. A., Aspar, D. G., & Staite, N. D. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360915 · Cited by 204
In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice.
Hom, J. T., Bendele, A. M., & Carlson, D. G. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.3.834 · Cited by 153
Geiger, T. M., Towbin, H., Cosenti-Vargas, A., Zingel, O., Arnold, J., Rordorf, C. M., Glatt, M., & Vosbeck, K. (1993) · PubMed · Cited by 115
Clinical management of rheumatoid arthritis
Brooks, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)92628-7 · Cited by 54
In vivo leukocyte migration in arthritis
Jones, A., AL-JANABI, M. A., Solanki, K., Sobnack, R., Greenwood, A., Doyle, D., Britton, K. E., & Huskisson, E. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340304 · Cited by 51
Pettipher, E. R., Salter, E. D., Breslow, R., Raycroft, L., & Showell, H. J. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13827.x · Cited by 36
Self-citationThe role of neutrophils in type II collagen-induced arthritis in rats.
Schrier, D. J., Rb, G., Lesch, M. E., & Fantone, J. C. (1984) · PubMed · Cited by 32
Cited by
Peters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease
Haeggström, J. Z., & Funk, C. D. (2011) · Chemical Reviews · doi:10.1021/cr200246d · Cited by 875
A Second Leukotriene B4 Receptor, Blt2
Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., & Shimizu, T. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.421 · Cited by 538
Nakagawa, T. Y., Brissette, W. H., Lira, P. D., Griffiths, R. J., Petrushova, N., Stock, J., McNeish, J. D., Eastman, S. E., Howard, E. D., Clarke, S. R. M., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80021-7 · Cited by 416
Self-citationCytosolic phospholipase A2: physiological function and role in disease
Leslie, C. C. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r057588 · Cited by 413
Metadata
- Authors
- Griffiths, R. J., Pettipher, E. R., Koch, K., Farrell, C. A., Breslow, R., Conklyn, M. J., Smith, M. A., Hackman, B. C., Wimberly, D. J., & Milici, A. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-01-17
- Volume
- 92
- Issue
- 2
- Pages
- 517-521
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2098532478
- Cited by
- 315
- References
- 17
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.